01 /What selectivity means
Receptor selectivity is the degree to which a compound binds its intended receptor over related receptors that share structural features. A perfectly selective compound binds only one receptor; a non selective compound binds many.
In peptide pharmacology, selectivity is typically measured as the ratio of binding affinity at the intended receptor versus binding affinity at off target receptors. A selectivity ratio of 100 means the compound binds the intended receptor 100 times more tightly than the off target receptor; a ratio of 10 means 10 times; a ratio of 1 means equally well.
02 /Why selectivity matters for research
Selective compounds make better research tools because they let you isolate one mechanism without confounding signal from related pathways. If a compound binds three receptors and produces an experimental outcome, you do not know which receptor mediated the outcome. If a compound binds one receptor cleanly, you do.
For protocol design, selectivity also means fewer off target effects to manage. A selective ghrelin receptor agonist like Ipamorelin produces growth hormone release without the cortisol or prolactin signal that less selective GHRPs produce.
03 /How peptides achieve selectivity
Peptide selectivity comes from sequence specific binding. The amino acid sequence of the peptide forms a three dimensional structure that fits the intended receptor binding pocket with high specificity. Small changes to the sequence can shift selectivity substantially; sequence engineering is the main lever for designing more selective research peptides.
Compared with small molecule drugs (which typically achieve selectivity through compact rigid structures), peptides achieve selectivity through more diffuse binding surfaces involving multiple residues. This makes peptides harder to design from scratch but also gives them an inherent advantage in selectivity for closely related receptors.
04 /Selectivity examples in the Apothify library
Ipamorelin is the canonical selective ghrelin receptor agonist. Published research shows minimal observed cortisol or prolactin signal at concentrations that produce robust growth hormone release. This selectivity profile makes Ipamorelin the standard choice when researchers want to study ghrelin pathway activation without confounders.
Pentapeptide-3 (Vialox) is a selective postsynaptic nicotinic acetylcholine receptor antagonist studied in cosmetic expression line research. Its selectivity profile distinguishes it from the SNARE complex modulating expression line peptides (Argireline, SNAP-8, Acetyl Hexapeptide-30) which target a different mechanism.
Endomorphin 1 and Endomorphin 2 are highly selective mu opioid receptor agonists. Their selectivity makes them reference ligands in mu receptor pharmacology research.
05 /When non selectivity is a feature
For some research questions, non selectivity is the point. Older generation GHRPs (GHRP 2, GHRP 6, Hexarelin) are less selective than Ipamorelin; they engage the ghrelin receptor but also produce cortisol and prolactin signal. For research interested in the broader pharmacology of growth hormone secretagogues across multiple downstream signals, the less selective compounds provide more data per experiment.
Multi receptor agonists like Tirzepatide (GIP plus GLP 1) and Retatrutide (GIP plus GLP 1 plus glucagon) are explicitly designed for non selectivity at the receptor family level. Their value as research tools and as therapeutic candidates comes from engaging multiple receptors simultaneously.
06 /Reading selectivity claims on peptide pages
The how it works section on each Apothify peptide page describes the receptor target. Where selectivity is established in the published literature, the language calls it out (selective agonist, highly selective ligand, reference compound in receptor selectivity research).
Where selectivity is broader or less well characterized, the language is more general (agonist at the X receptor, engages X pathway). Absence of a selectivity claim does not mean the compound is non selective; it means the published research has not specifically characterized selectivity at the same level as compounds where the claim is made.
07 /Practical implications for protocol design
If your research question is narrow (you want to study one specific receptor pathway cleanly), pick the most selective compound available for that target.
If your research question is broad (you want to map the response across a receptor family), a less selective compound may produce more useful data per experiment.
If you are combining two compounds, selectivity affects interaction predictability. Two selective compounds targeting independent receptors produce predictable additive or synergistic effects. Two less selective compounds produce a more complicated profile that is harder to interpret.
08 /Selectivity in the interaction matrix
The Apothify interaction matrix encodes some selectivity considerations indirectly. Two selective same receptor compounds get a redundant flag. Two selective different receptor compounds get either a synergy flag (if the receptors converge on a complementary end signal) or no flag (if the receptors are unrelated).
Selectivity is not directly visible in the matrix output. It is encoded in the underlying logic and in the per peptide page descriptions.
09 /Where this matters most
Receptor selectivity is most consequential in the growth hormone category (Ipamorelin vs other GHRPs), the cosmetic expression line category (Pentapeptide-3 vs Argireline family), and the opioid category (Endomorphin compounds as selective mu agonists vs less selective opioid peptides). Reading selectivity claims carefully in these categories prevents confused protocol design.
